Contract research
It is a long path from the development of an active pharmaceutical ingredient in the lab to an effective drug – a process that takes several years. Campus companies are often involved in this process on behalf of the pharmaceutical and biotech industry or academic groups.
The company Experimental Pharmacology & Oncology Berlin-Buch (EPO) is a leader in preclinical cancer research in Germany. Worldwide, EPO offers customized and comprehensive service for the preclinical development of novel cancer drugs and is specialized in the development of individualized tumor models.
News innovation
Students from Freie Universität Berlin visited the Campus Berlin-Buch
Master's students in Biology at Freie Universität Berlin learned about career opportunities and start-ups at the BiotechPark Berlin-Buch on June 11, 2025.
more ...Berlin-Buch goes Boston
At BIO 2025, June 16-19 in Boston, Campus Berlin-Buch GmbH will be showcasing the location of future innovation Berlin-Buch
more ...Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany
Eckert & Ziegler (ISIN DE0005659700, SDAX) congratulates Telix Pharmaceuticals Limited (Telix) on the approval of its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-6...
more ...Events Campus
28.06.2025, 16:00
Lange Nacht der Wissenschaften 2025
Mitmach-Experimente, Shows, Laborführungen
more ...
